178 related articles for article (PubMed ID: 34617875)
1. An ocular adverse event in temporal association with COVID-19 vaccination in a patient with systemic lupus erythematosus: a case report.
Jin W; Tang Y; Wen C
Hum Vaccin Immunother; 2021 Nov; 17(11):4102-4104. PubMed ID: 34617875
[TBL] [Abstract][Full Text] [Related]
2. Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey.
Tang Q; Li F; Tian J; Kang J; He J
Clin Exp Med; 2023 Jun; 23(2):457-463. PubMed ID: 35612692
[TBL] [Abstract][Full Text] [Related]
3. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
Zavala-Flores E; Salcedo-Matienzo J; Quiroz-Alva A; Berrocal-Kasay A
Clin Rheumatol; 2022 May; 41(5):1349-1357. PubMed ID: 34782941
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of newly diagnosed systemic lupus erythematosus after SARS-CoV-2 vaccination.
Moriyama M; Noda K; Ito H; Matsushita T; Kurosaka D
Mod Rheumatol Case Rep; 2023 Dec; 8(1):63-68. PubMed ID: 37348045
[TBL] [Abstract][Full Text] [Related]
5. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management.
Mehta P; Gasparyan AY; Zimba O; Kitas GD
Clin Rheumatol; 2022 Sep; 41(9):2893-2910. PubMed ID: 35639259
[TBL] [Abstract][Full Text] [Related]
6. Systemic Lupus Erythematosus and COVID-19.
Pappa M; Panagiotopoulos A; Thomas K; Fanouriakis A
Curr Rheumatol Rep; 2023 Oct; 25(10):192-203. PubMed ID: 37477841
[TBL] [Abstract][Full Text] [Related]
7. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis.
Bartels LE; Ammitzbøll C; Andersen JB; Vils SR; Mistegaard CE; Johannsen AD; Hermansen MF; Thomsen MK; Erikstrup C; Hauge EM; Troldborg A
Rheumatol Int; 2021 Nov; 41(11):1925-1931. PubMed ID: 34476603
[TBL] [Abstract][Full Text] [Related]
8. Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination. A case report.
Molina-Rios S; Rojas-Martinez R; Estévez-Ramirez GM; Medina YF
Mod Rheumatol Case Rep; 2023 Jan; 7(1):43-46. PubMed ID: 35246682
[TBL] [Abstract][Full Text] [Related]
9. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus.
Yoshida T; Tsuji H; Onishi A; Takase Y; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Tanaka M; Yoshifuji H; Morinobu A
Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35961691
[TBL] [Abstract][Full Text] [Related]
10. Systemic lupus erythematosus following COVID-19 vaccination. A systematic review of case reports and case series.
Cahuapaza-Gutierrez NL
Lupus; 2024 Apr; 33(4):375-386. PubMed ID: 38315894
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series.
Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Kittanamongkolchai W
RMD Open; 2021 Dec; 7(3):. PubMed ID: 34862313
[TBL] [Abstract][Full Text] [Related]
12. Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study.
Jiang X; Sparks J; Wallace Z; Deng X; Li H; Lu N; Xie D; Wang Y; Zeng C; Lei G; Wei J; Zhang Y
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36889799
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
14. Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.
Mok CC; Chan KL; Tse SM
Vaccine; 2022 Sep; 40(41):5959-5964. PubMed ID: 36085256
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance.
Tan SYS; Yee AM; Sim JJL; Lim CC
Rheumatology (Oxford); 2023 May; 62(5):1757-1772. PubMed ID: 36271852
[TBL] [Abstract][Full Text] [Related]
16. Lupus, vaccinations and COVID-19: What we know now.
Mason A; Anver H; Lwin M; Holroyd C; Faust SN; Edwards CJ
Lupus; 2021 Sep; 30(10):1541-1552. PubMed ID: 34134555
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus.
Giannopoulou N; Gupta L; Andreoli L; Lini D; ; Nikiphorou E; Aggarwal R; Agarwal V; Parodis I
Autoimmun Rev; 2023 Apr; 22(4):103292. PubMed ID: 36740090
[TBL] [Abstract][Full Text] [Related]
18. Systemic lupus erythematosus after COVID-19 vaccination: A case report.
Patil S; Patil A
J Cosmet Dermatol; 2021 Oct; 20(10):3103-3104. PubMed ID: 34418261
[No Abstract] [Full Text] [Related]
19. Systemic lupus erythematosus flare during SARS-CoV-2 infection: Report of 3 cases presented during the fourth wave of the pandemic in Colombia.
Naranjo-Millán JA; Bedoya-Joaqui V; Cañas CA
Int J Rheum Dis; 2023 Sep; 26(9):1807-1810. PubMed ID: 36880687
[TBL] [Abstract][Full Text] [Related]
20. Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
Barbhaiya M; Levine JM; Siegel CH; Bykerk VP; Jannat-Khah D; Mandl LA
Clin Rheumatol; 2022 May; 41(5):1619-1622. PubMed ID: 34716843
[No Abstract] [Full Text] [Related]
[Next] [New Search]
